Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
NeuroSense Therapeutics Ltd. (NRSN) had Normalized Income after Taxes of $-11.28M for the most recently reported fiscal year, ending 2023-12-31.
Income Statement Financials | |
-- |
|
$-11.28M |
|
-- |
|
-- |
|
$13.30M |
|
$-13.30M |
|
$2.02M |
|
$-11.28M |
|
$-11.28M |
|
$-11.28M |
|
$-11.28M |
|
$-11.28M |
|
Normalized Income after Taxes |
$-11.28M |
$-13.30M |
|
$-13.21M |
|
13.64M |
|
13.64M |
|
$-0.83 |
|
$-0.83 |
|
Balance Sheet Financials | |
$2.92M |
|
$0.09M |
|
$0.26M |
|
$3.18M |
|
$3.46M |
|
$0.07M |
|
$1.59M |
|
$5.05M |
|
$-1.87M |
|
$-1.87M |
|
$-1.87M |
|
15.38M |
|
Cash Flow Statement Financials | |
$-8.45M |
|
$3.65M |
|
$3.90M |
|
$3.54M |
|
$2.64M |
|
$-0.90M |
|
$2.80M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
0.84 |
|
-- |
|
-- |
|
-0.04 |
|
-0.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
601.92% |
|
601.92% |
|
-355.16% |
|
626.32% |
|
$-0.12 |
|
$-0.62 |
|
$-0.62 |